Forward-Looking Statements
This release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 including without limitation statements regarding our continued momentum across regions and business units, our growth opportunities, strategies and related acceleration, the ability of our continued focus in systems and enterprise software to serve as a foundation to deliver sustainable growth while creating value for all our stakeholders, confidence in our ability to ship backlog and optimism in the continued strength in our business as we continue to align resources to higher growth opportunities in pursuit of our long-term financial model, and our guidance and expectations for our Q2 2021 GAAP and non-GAAP revenue, GAAP and non-GAAP EPS, and our estimated 2021 non-GAAP effective tax rate. These statements are subject to a number of risks and uncertainties, and actual results may differ materially from any future results expressed or implied by the forward-looking statements. Risks and uncertainties include without limitation: the effect of the global economic and geopolitical conditions; our international operations and foreign economies; adverse public health matters, including epidemics and pandemics such as the COVID-19 pandemic; our ability to effectively manage our partners and distribution channels; interruptions in our technology systems; cyber-attacks; the dependency of our product revenue on certain industries and the risk of contractions in such industries; fluctuations in demand for our products including orders from our large customers; concentration of credit risk and uncertain conditions in the global financial markets; our ability to compete in markets that are highly competitive; our ability to release successful new products or achieve expected returns; the risk that our manufacturing capacity and a substantial majority of our warehousing and distribution capacity are located outside of the U.S.; our dependence on key suppliers and distributors; component shortages; longer delivery lead times from our suppliers; risk of product liability claims; dependence on our proprietary rights and risks of intellectual property litigation; the continued service of key management and technical personnel; the ability to comply with environmental laws and associated costs; our ability to maintain our website; the risks of bugs, vulnerabilities, errors or design flaws in our products; our ability to achieve the benefits of employee restructuring plans; our exposure to large orders; our ability to effectively manage our operating expenses and meet budget; expense overruns; manufacturing inefficiencies and the level of capacity utilization; fluctuations in our quarterly results due to factors outside of our control; our outstanding debt; our revenues are subject to seasonal variation; our ability to comply with laws and regulations; changes in tax rates and exposure to additional tax liabilities; our ability to make certain acquisitions or dispositions, integrate the companies we acquire or separate the companies we sold and/or enter into strategic relationships; risks related to currency fluctuations; adverse effects of price changes; and changes in accounting principles. The company directs readers to its Form 10-K for the year ended Dec. 31, 2020, and the other documents it files with the SEC for other risks associated with the company’s future performance. These documents contain and identify important factors that could cause our actual results to differ materially from those contained in our forward-looking statements.
All information in this release is as of the date above. The company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company’s expectations.
About NI
NI (ni.com) develops high-performance automated test and automated measurement systems to help you solve your engineering challenges now and into the future. Our open, software-defined platform uses modular hardware and an expansive ecosystem to help you turn powerful possibilities into real solutions. (NATI-F)
National Instruments, NI and ni.com are trademarks of National Instruments. Other product and company names listed are trademarks or trade names of their respective companies.
National Instruments |
||||||||
Condensed Consolidated Balance Sheets |
||||||||
(in thousands) |
||||||||
|
March 31, |
|
December 31, |
|||||
|
2021 |
|
2020 |
|||||
|
(unaudited) |
|
|
|||||
Assets |
|
|
||||||
Cash and cash equivalents |
$ |
266,712 |
|
$ |
260,232 |
|
||
Short-term investments |
32,171 |
|
59,923 |
|
||||
Accounts receivable, net |
241,088 |
|
266,869 |
|
||||
Inventories, net |
197,179 |
|
194,012 |
|
||||
Prepaid expenses and other current assets |
75,674 |
|
68,470 |
|
||||
Total current assets |
812,824 |
|
849,506 |
|
||||
Property and equipment, net |
252,320 |
|
254,399 |
|
||||
Goodwill |
462,646 |
|
467,547 |
|
||||
Intangible assets, net |
159,639 |
|
172,719 |
|
||||
Operating lease right-of-use assets |
61,478 |
|
67,674 |
|
||||
Other long-term assets |
77,059 |
|
72,643 |
|
||||
Total assets |
$ |
1,825,966 |
|
$ |
1,884,488 |
|
||
|
|
|
||||||
Liabilities and Stockholders' Equity |
|
|
||||||
Accounts payable and accrued liabilities |
$ |
54,686 |
|
$ |
51,124 |
|
||
Accrued compensation |
58,201 |
|
87,068 |
|
||||
Deferred revenue - current |
128,740 |
|
132,151 |
|
||||
Operating lease liabilities - current |
14,751 |
|
15,801 |
|
||||
Other taxes payable |
35,836 |
|
48,129 |
|
||||
Debt - current |
5,000 |
|
5,000 |
|
||||
Other current liabilities |
42,221 |
|
42,578 |
|
||||
Total current liabilities |
339,435 |
|
381,851 |
|
||||
Deferred income taxes |
25,050 |
|
25,288 |
|
||||
Liability for uncertain tax positions |
10,933 |
|
10,868 |
|
||||
Income tax payable - non-current |
61,622 |
|
61,623 |
|
||||
Deferred revenue - non-current |
35,065 |
|
36,335 |
|
||||
Operating lease liabilities - non-current |
31,644 |
|
35,854 |
|
||||
Debt - non-current |
90,991 |
|
92,036 |
|
||||
Other long-term liabilities |
9,717 |
|
15,762 |
|
||||
Total liabilities |
$ |
604,457 |
|
$ |
659,617 |
|
||
|
|
|
||||||
Stockholders' equity: |
|
|
||||||
Preferred stock |
$ |
— |
|
$ |
— |
|
||
Common stock |
1,316 |
|
1,312 |
|
||||
Additional paid-in capital |
1,059,018 |
|
1,033,284 |
|
||||
Retained earnings |
180,063 |
|
211,101 |
|
||||
Accumulated other comprehensive loss |
(18,888) |
|
(20,826) |
|
||||
Total stockholders' equity |
1,221,509 |
|
1,224,871 |
|
||||
Total liabilities and stockholders' equity |
$ |
1,825,966 |
|
$ |
1,884,488 |
|
National Instruments |
||||||||
Condensed Consolidated Statements of Income |
||||||||
(in thousands, except per share data, unaudited) |
||||||||
|
|
|
||||||
|
Three Months Ended |
|||||||
|
March 31, |
|||||||
|
2021 |
2020 |
||||||
Net sales: |
|
|
||||||
Product |
$ |
295,092 |
|
$ |
273,978 |
|
||
Software maintenance |
40,090 |
|
35,403 |
|
||||
Total net sales |
335,182 |
|
309,381 |
|
||||
|
|
|
||||||
Cost of sales: |
|
|
||||||
Product |
91,657 |
|
82,071 |
|
||||
Software maintenance |
3,757 |
|
1,690 |
|
||||
Total cost of sales |
95,414 |
|
83,761 |
|
||||
|
|
|
||||||
Gross profit |
239,768 |
|
225,620 |
|
||||
|
|
|
||||||
Operating expenses: |
|
|
||||||
Sales and marketing |
116,783 |
|
115,746 |
|
||||
Research and development |
80,086 |
|
71,621 |
|
||||
General and administrative |
33,358 |
|
26,180 |
|
||||
Total operating expenses |
230,227 |
|
213,547 |
|
||||
Gain on sale of business/assets |
— |
|
159,753 |
|
||||
Operating income |
9,541 |
|
171,826 |
|
||||
|
|
|
||||||
Other (expense) income: |
(5,070) |
|
560 |
|
||||
|
|
|
||||||
Income before income taxes |
4,471 |
|
172,386 |
|
||||
|
|
|
||||||
(Benefit) provision for income taxes |
(24) |
|
39,731 |
|
||||
|
|
|
||||||
Net income |
$ |
4,495 |
|
$ |
132,655 |
|
||
|
|
|
||||||
Basic earnings per share |
$ |
0.03 |
|
$ |
1.02 |
|
||
Diluted earnings per share |
$ |
0.03 |
|
$ |
1.01 |
|
||
|
|
|
||||||
Weighted average shares outstanding - |
|
|
||||||
Basic |
131,483 |
|
130,613 |
|
||||
Diluted |
132,717 |
|
131,357 |
|
||||
|
|
|
||||||
Dividends declared per share |
$ |
0.27 |
|
$ |
0.26 |
|
National Instruments |
||||||||
Condensed Consolidated Statements of Cash Flows |
||||||||
(in thousands, unaudited) |
||||||||
|
Three Months Ended |
|||||||
|
March 31, |
|||||||
|
2021 |
|
2020 |
|||||
Cash flow from operating activities: |
|
|
||||||
Net income |
$ |
4,495 |
|
$ |
132,655 |
|
||
Adjustments to reconcile net income to net cash provided by operating activities: |
|
|
||||||
Disposal gain on sale of business/assets |
— |
|
(159,753) |
|
||||
Depreciation and amortization |
23,872 |
|
19,265 |
|
||||
Stock-based compensation |
17,189 |
|
12,104 |
|
||||
Loss from equity-method investees |
4,173 |
|
1,025 |
|
||||
Deferred income taxes |
(3,746) |
|
(1,599) |
|
||||
Net change in operating assets and liabilities |
(16,142) |
|
39,923 |
|
||||
Net cash provided by operating activities |
29,841 |
|
43,620 |
|
||||
|
|
|
||||||
Cash flow from investing activities: |
|
|
||||||
Capital expenditures |
(8,488) |
|
(12,816) |
|
||||
Proceeds from sale of business/assets |
— |
|
158,973 |
|
||||
Capitalization of internally developed software |
(226) |
|
(1,915) |
|
||||
Additions to other intangibles |
(1,018) |
|
(112) |
|
||||
Acquisitions of equity-method investments |
(11,539) |
|
— |
|
||||
Purchases of short-term investments |
— |
|
(206,331) |
|
||||
Sales and maturities of short-term investments |
27,664 |
|
111,827 |
|
||||
Net cash provided by investing activities |
6,393 |
|
49,626 |
|
||||
|
|
|
||||||
Cash flow from financing activities: |
|
|
||||||
Payments on term loan |
(1,250) |
|
— |
|
||||
Proceeds from issuance of common stock |
8,565 |
|
8,991 |
|
||||
Repurchase of common stock |
— |
|
(6,526) |
|
||||
Dividends paid |
(35,533) |
|
(33,997) |
|
||||
Net cash used by financing activities |
(28,218) |
|
(31,532) |
|
||||
|
|
|
||||||
Impact of changes in exchange rates on cash |
(1,536) |
|
(1,889) |
|
||||
|
|
|
||||||
Net change in cash and cash equivalents |
6,480 |
|
59,825 |
|
||||
Cash and cash equivalents at beginning of period |
260,232 |
|
194,616 |
|
||||
Cash and cash equivalents at end of period |
$ |
266,712 |
|
$ |
254,441 |
|
The following tables provide details with respect to the amount of GAAP charges related to stock-based compensation, amortization of acquisition-related intangibles and fair value adjustments, acquisition-related transaction costs, capitalization and amortization of internally developed software costs, disposal gains on sale of business, impairment losses on equity-method investments and restructuring charges that were recorded in the line items indicated below (unaudited) (in thousands): |
||||||||
|
Three Months Ended |
|||||||
|
March 31, |
|||||||
|
2021 |
|
2020 |
|||||
Stock-based compensation |
|
|
||||||
Cost of sales |
$ |
1,113 |
|
$ |
804 |
|
||
Sales and marketing |
5,696 |
|
5,175 |
|
||||
Research and development |
5,714 |
|
3,520 |
|
||||
General and administrative |
4,666 |
|
2,603 |
|
||||
Provision for income taxes |
(3,324) |
|
(1,502) |
|
||||
Total |
$ |
13,865 |
|
$ |
10,600 |
|
||
|
|
|
||||||
Amortization of acquisition-related intangibles and fair value adjustments |
|
|
||||||
Net sales |
$ |
813 |
|
$ |
— |
|
||
Cost of sales |
4,272 |
|
746 |
|
||||
Sales and marketing |
2,171 |
|
486 |
|
||||
Research and development |
— |
|
28 |
|
||||
Other (expense) income |
394 |
|
124 |
|
||||
Provision for income taxes |
(975) |
|
(157) |
|
||||
Total |
$ |
6,675 |
|
$ |
1,227 |
|
||
|
|
|
||||||
Acquisition-related transaction and integration costs, restructuring charges and other (1) |
|
|
||||||
Cost of sales |
$ |
75 |
|
$ |
20 |
|
||
Sales and marketing |
4,648 |
|
6,373 |
|
||||
Research and development |
488 |
|
4,669 |
|
||||
General and administrative |
5,666 |
|
(1,014) |
|
||||
Gain on sale of business/assets (1) |
— |
|
(159,753) |
|
||||
Other (expense) income (2) |
3,725 |
|
128 |
|
||||
Provision for income taxes |
(2,883) |
|
34,754 |
|
||||
Total |
$ |
11,719 |
|
$ |
(114,823) |
|
||
(1): During the first quarter of 2020, the company recognized a gain of approximately $160 million related to the divestiture of AWR, presented within "Gain on sale of business/assets". |
||||||||
(2): During the first quarter of 2021, we recognized a $3.5 million impairment loss related to one of our equity-method investments, presented within "Other (expense) income" |
||||||||
|
|
|
||||||
(Capitalization) and amortization of internally developed software costs |
|
|
||||||
Cost of sales |
$ |
6,874 |
|
$ |
7,082 |
|
||
Research and development |
(226) |
|
(1,915) |
|
||||
Provision for income taxes |
(1,396) |
|
(1,085) |
|
||||
Total |
$ |
5,252 |
$ |
4,082 |
National Instruments |
||||||||
Reconciliation of GAAP to Non-GAAP Measures |
||||||||
(in thousands, unaudited) |
||||||||
|
Three Months Ended |
|||||||
|
March 31, |
|||||||
|
2021 |
|
2020 |
|||||
Reconciliation of Net Sales to Non-GAAP Net Sales |
||||||||
Net sales, as reported |
$ |
335,182 |
|
$ |
309,381 |
|
||
Impact of acquisition-related fair value adjustments |
813 |
|
— |
|
||||
Non-GAAP net sales |
$ |
335,995 |
|
$ |
309,381 |
|
||
|
|
|
||||||
Reconciliation of Gross Profit to Non-GAAP Gross Profit |
||||||||
Gross profit, as reported |
$ |
239,768 |
|
$ |
225,620 |
|
||
Stock-based compensation |
1,113 |
|
804 |
|
||||
Amortization of acquisition-related intangibles and fair value adjustments |
5,085 |
|
746 |
|
||||
Acquisition transaction and integration costs. restructuring charges and other |
75 |
|
20 |
|
||||
Amortization of internally developed software costs |
6,874 |
|
7,082 |
|
||||
Non-GAAP gross profit |
$ |
252,915 |
|
$ |
234,272 |
|
||
Non-GAAP gross margin |
75.3 |
% |
75.7 |
% |
||||
|
|
|
||||||
Reconciliation of Operating Expenses to Non-GAAP Operating Expenses |
||||||||
Operating expenses, as reported |
$ |
230,227 |
|
$ |
213,547 |
|
||
Stock-based compensation |
(16,076 |
) |
(11,298 |
) |
||||
Amortization of acquisition-related intangibles and fair value adjustments |
(2,171 |
) |
(514 |
) |
||||
Acquisition transaction and integration costs. restructuring charges and other |
(10,802 |
) |
(10,028 |
) |
||||
Capitalization of internally developed software costs |
226 |
|
1,915 |
|
||||
Non-GAAP operating expenses |
$ |
201,404 |
|
$ |
193,622 |
|
||
|
|
|
||||||
Reconciliation of Operating Income to Non-GAAP Operating Income |
||||||||
Operating income, as reported |
$ |
9,541 |
|
$ |
171,826 |
|
||
Stock-based compensation |
17,189 |
|
12,102 |
|
||||
Amortization of acquisition-related intangibles and fair value adjustments |
7,256 |
|
1,260 |
|
||||
Acquisition transaction and integration costs. restructuring charges and other |
10,877 |
|
10,048 |
|
||||
Net amortization of internally developed software costs |
6,648 |
|
5,167 |
|
||||
Gain on sale of business/assets |
— |
|
(159,753 |
) |
||||
Non-GAAP operating income |
$ |
51,511 |
|
$ |
40,650 |
|
||
Non-GAAP operating margin |
15.3 |
% |
13.1 |
% |
||||
|
|
|
||||||
Reconciliation of Provision for income taxes to Non-GAAP Provision for income taxes |
||||||||
Provision for income taxes, as reported (1) |
$ |
(24 |
) |
$ |
39,731 |
|
||
Stock-based compensation |
3,324 |
|
1,502 |
|
||||
Amortization of acquisition-related intangibles and fair value adjustments |
975 |
|
157 |
|
||||
Acquisition transaction and integration costs. restructuring charges and other |
2,883 |
|
1,615 |
|
||||
Net amortization of internally developed software costs |
1,396 |
|
1,085 |
|
||||
Gain on sale of business/assets |
— |
|
(36,369 |
) |
||||
Non-GAAP provision for income taxes (1) |
$ |
8,554 |
|
$ |
7,721 |
|
||
(1): The income tax effect related to each non-GAAP item is calculated based on the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment, and considers the current and deferred tax impact of those adjustments. |
Reconciliation of GAAP Net Income and Diluted EPS to Non-GAAP Net Income and Non-GAAP Diluted EPS |
||||||||
(in thousands, except per share data, unaudited) |
||||||||
|
|
|
|
|
||||
|
|
Three Months Ended |
||||||
|
|
March 31, |
||||||
|
|
2021 |
|
2020 |
||||
Net income, as reported |
$ |
4,495 |
|
$ |
132,655 |
|
||
Adjustments to reconcile net income to non-GAAP net income: |
|
|
||||||
Stock-based compensation |
17,189 |
|
12,102 |
|
||||
Amortization of acquisition-related intangibles and fair value adjustments |
7,650 |
|
1,384 |
|
||||
Acquisition transaction and integration costs. restructuring charges and other |
14,602 |
|
10,176 |
|
||||
Net amortization of internally developed software costs |
6,648 |
|
5,167 |
|
||||
Gain on sale of business/assets |
— |
|
(159,753) |
|
||||
Income tax effects and adjustments (1) |
(8,578) |
|
32,010 |
|
||||
Non-GAAP net income |
$ |
42,006 |
|
$ |
33,741 |
|
||
Non-GAAP net margin |
12.5 |
% |
10.9 |
% |
||||
|
|
|
||||||
Diluted EPS, as reported |
$ |
0.03 |
|
$ |
1.01 |
|
||
Adjustment to reconcile diluted EPS to non-GAAP diluted EPS |
|
|
||||||
Impact of stock-based compensation |
0.13 |
|
0.09 |
|
||||
Impact of amortization of acquisition-related intangibles and fair value adjustments |
0.06 |
|
0.01 |
|
||||
Impact of acquisition transaction and integration costs, restructuring charges and other |
0.11 |
|
0.08 |
|
||||
Impact of amortization of internally developed software costs |
0.05 |
|
0.04 |
|
||||
Impact of gain on sale of business/assets |
— |
|
(1.22) |
|
||||
Income tax effects and adjustments (1) |
(0.06) |
|
0.25 |
|
||||
Non-GAAP diluted EPS |
$ |
0.32 |
|
$ |
0.26 |
|
||
(1): The income tax effect related to each non-GAAP item is calculated based on the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment, and considers the current and deferred tax impact of those adjustments. |
||||||||
|
|
|
||||||
Weighted average shares outstanding - |
|
|
||||||
Basic |
131,483 |
|
130,613 |
|
||||
Diluted |
132,717 |
|
131,357 |
|
National Instruments |
||||||||
Reconciliation of Net Income to EBITDA |
||||||||
(in thousands, unaudited) |
||||||||
|
|
|
||||||
|
Three Months Ended |
|||||||
|
March 31, |
|||||||
|
2021 |
|
2020 |
|||||
Net income, as reported |
$ |
4,495 |
|
$ |
132,655 |
|
||
Adjustments to reconcile net income to EBITDA: |
|
|
||||||
Interest expense (income), net |
543 |
|
(2,223) |
|
||||
Tax (benefit) expense |
(24) |
|
39,731 |
|
||||
Depreciation and amortization |
23,872 |
|
19,265 |
|
||||
EBITDA |
$ |
28,886 |
|
$ |
189,428 |
|
||
Weighted average shares outstanding - Diluted |
132,717 |
|
131,357 |
|
||||
|
|
|
Reconciliation of GAAP to Non-GAAP Diluted EPS Guidance |
||||||||
(unaudited) |
||||||||
|
|
Three Months Ended |
||||||
|
|
June 30, 2021 |
||||||
|
|
|
|
|
||||
|
|
Low |
|
High |
||||
GAAP Diluted EPS, guidance |
$ |
(0.02 |
) |
$ |
0.12 |
|
||
Adjustment to reconcile diluted EPS to non-GAAP diluted EPS: |
|
|
||||||
Stock-based compensation |
0.15 |
|
0.15 |
|
||||
Amortization of acquisition-related intangibles and fair value adjustments |
0.06 |
|
0.06 |
|
||||
Acquisition transaction and integration costs, restructuring charges and other |
0.04 |
|
0.04 |
|
||||
Net amortization of internally developed software costs |
0.05 |
|
0.05 |
|
||||
Income tax effects and adjustments (1) |
(0.07 |
) |
(0.07 |
) |
||||
Non-GAAP Diluted EPS, guidance |
$ |
0.21 |
|
$ |
0.35 |
|
||
(1): The income tax effect related to each non-GAAP item is calculated based on the tax laws and statutory income tax rates applicable in the tax jurisdiction(s) of the underlying non-GAAP adjustment, and considers the current and deferred tax impact of those adjustments. |
Reconciliation of GAAP Net Sales to Non-GAAP Net Sales, Guidance |
||||||||||
(unaudited) |
||||||||||
|
Three Months Ended |
|
|
|||||||
|
June 30, |
|
|
|||||||
|
2021 |
2020 |
|
|
||||||
|
(midpoint) |
|
|
Percent Inc(Dec) |
||||||
GAAP Net sales, guidance |
$ |
319,250 |
|
$ |
301,329 |
|
6% |
|||
Impact of purchase accounting fair value adjustments |
750 |
|
— |
|
|
|||||
Non-GAAP Net sales, guidance |
$ |
320,000 |
|
$ |
301,329 |
|
6% |